Pieris Pharmaceuticals (PIRS) Competitors $13.60 -2.53 (-15.69%) (As of 12/13/2024) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends PIRS vs. ZIVO, ANVS, RPTX, OPTN, VTGN, VOR, VHAQ, DBVT, BCAB, and CUEShould you be buying Pieris Pharmaceuticals stock or one of its competitors? The main competitors of Pieris Pharmaceuticals include ZIVO Bioscience (ZIVO), Annovis Bio (ANVS), Repare Therapeutics (RPTX), OptiNose (OPTN), Vistagen Therapeutics (VTGN), Vor Biopharma (VOR), Viveon Health Acquisition (VHAQ), DBV Technologies (DBVT), BioAtla (BCAB), and Cue Biopharma (CUE). These companies are all part of the "pharmaceutical products" industry. Pieris Pharmaceuticals vs. ZIVO Bioscience Annovis Bio Repare Therapeutics OptiNose Vistagen Therapeutics Vor Biopharma Viveon Health Acquisition DBV Technologies BioAtla Cue Biopharma ZIVO Bioscience (NASDAQ:ZIVO) and Pieris Pharmaceuticals (NASDAQ:PIRS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, community ranking, profitability, institutional ownership and media sentiment. Which has stronger valuation & earnings, ZIVO or PIRS? ZIVO Bioscience has higher earnings, but lower revenue than Pieris Pharmaceuticals. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Pieris Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZIVO Bioscience$15.85K4,250.73-$7.78M-$4.88-3.89Pieris Pharmaceuticals$42.81M0.42-$24.54M-$12.10-1.12 Is ZIVO or PIRS more profitable? Pieris Pharmaceuticals has a net margin of -39.71% compared to ZIVO Bioscience's net margin of -11,068.75%. ZIVO Bioscience's return on equity of 0.00% beat Pieris Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ZIVO Bioscience-11,068.75% N/A -2,240.92% Pieris Pharmaceuticals -39.71%-80.93%-59.55% Do analysts prefer ZIVO or PIRS? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Pieris Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals hold more shares of ZIVO or PIRS? 12.8% of ZIVO Bioscience shares are held by institutional investors. Comparatively, 40.1% of Pieris Pharmaceuticals shares are held by institutional investors. 21.5% of ZIVO Bioscience shares are held by insiders. Comparatively, 6.4% of Pieris Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk and volatility, ZIVO or PIRS? ZIVO Bioscience has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500. Comparatively, Pieris Pharmaceuticals has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Does the MarketBeat Community believe in ZIVO or PIRS? Pieris Pharmaceuticals received 179 more outperform votes than ZIVO Bioscience when rated by MarketBeat users. However, 60.74% of users gave ZIVO Bioscience an outperform vote while only 60.30% of users gave Pieris Pharmaceuticals an outperform vote. CompanyUnderperformOutperformZIVO BioscienceOutperform Votes9960.74% Underperform Votes6439.26% Pieris PharmaceuticalsOutperform Votes27860.30% Underperform Votes18339.70% Does the media favor ZIVO or PIRS? In the previous week, Pieris Pharmaceuticals had 1 more articles in the media than ZIVO Bioscience. MarketBeat recorded 2 mentions for Pieris Pharmaceuticals and 1 mentions for ZIVO Bioscience. ZIVO Bioscience's average media sentiment score of 0.99 beat Pieris Pharmaceuticals' score of 0.00 indicating that ZIVO Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ZIVO Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pieris Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryZIVO Bioscience and Pieris Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Ad Porter & CompanyAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.I urge you to watch it now. Get Pieris Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PIRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PIRS vs. The Competition Export to ExcelMetricPieris PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.95M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-1.1210.5990.0517.18Price / Sales0.42195.801,117.00116.99Price / CashN/A57.1642.9637.86Price / Book0.635.094.784.78Net Income-$24.54M$151.83M$120.31M$225.60M7 Day PerformanceN/A-2.13%-1.92%-1.23%1 Month Performance-15.37%-3.10%11.50%3.36%1 Year Performance9.75%11.54%30.59%16.60% Pieris Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PIRSPieris Pharmaceuticals1.3025 of 5 stars$13.60-15.7%N/A+11.9%$17.95M$42.81M-1.12140Gap DownZIVOZIVO BioscienceN/A$20.00+0.8%N/A+1,307.4%$71M$30,000.00-4.0710News CoverageGap DownANVSAnnovis Bio2.3121 of 5 stars$5.12-3.6%$32.17+528.3%-59.3%$70.64MN/A-1.193News CoverageRPTXRepare Therapeutics3.4043 of 5 stars$1.64-7.3%$7.00+326.8%-79.7%$69.72M$51.13M-0.89180High Trading VolumeOPTNOptiNose4.0257 of 5 stars$0.46-2.7%$3.00+554.7%-63.1%$69.11M$70.99M0.00190VTGNVistagen Therapeutics0.9756 of 5 stars$2.48+2.1%N/A-50.3%$69.04M$1.06M-1.9640VORVor Biopharma2.5513 of 5 stars$0.99+0.1%$11.36+1,044.2%-62.1%$68.16MN/A-0.60140VHAQViveon Health AcquisitionN/A$10.00flatN/AN/A$66.49MN/A0.002DBVTDBV Technologies3.5378 of 5 stars$3.22-9.8%$22.50+598.8%-66.8%$66.24M$15.73M-0.73106Gap DownBCABBioAtla2.4604 of 5 stars$1.37-5.9%$6.00+339.6%-65.7%$65.99M$11M-0.8560News CoverageGap DownCUECue Biopharma4.6871 of 5 stars$1.04+10.6%$5.00+380.8%-63.1%$65.88M$9.53M-1.1660News CoveragePositive News Related Companies and Tools Related Companies ZIVO Bioscience Alternatives Annovis Bio Alternatives Repare Therapeutics Alternatives OptiNose Alternatives Vistagen Therapeutics Alternatives Vor Biopharma Alternatives Viveon Health Acquisition Alternatives DBV Technologies Alternatives BioAtla Alternatives Cue Biopharma Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PIRS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pieris Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pieris Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PIRS Stock Alerts